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COVID-19-associated 
risks and effects in 
myasthenia gravis 
(CARE-MG)
During the COVID-19 pandemic, 
patients with neuromuscular dis-
orders, especially patients with auto-
immune myasthenia gravis, might 
be at greater risk of worse outcomes 
than other wise healthy people 
because of an immunocompromised 
state rela ted to immunotherapy 
and possible respiratory and bulbar 
muscu lar weakness. However, cessa-
tion of immunotherapy in neuro-
inflammatory disorders has severe 
risks as well.1 Moreover, infections 
are a well recognised trigger of symp-
tom exacerbation in patients with 
myasthenia gravis, and some drugs 
used in therapeutic trials early in 
the pandemic, including hydroxy-
chloroquine2 and azithromycin,3 can 
provoke symptom exacerbations.
As there was no real-world evidence 
available at the onset of this pan-
demic and heightened concern existed 
for possible misinformation, an 
international group of neuromuscular 
physi cians developed initial guidelines 
for managing myasthenia gravis, 
which were based on previous 
experience with viral illnesses in this 
patient popu lation.4 However, the 
need for data to answer key clinical 
questions was quickly recognised and 
a registry was created to capture high-
quality information about outcomes 
for patients with myasthenia gravis 
and laboratory-confirmed, or clinically 
suspected, COVID-19. This physician-
reported registry, COVID-19 Associated 
Risks and Effects in Myasthenia 
Gravis (CARE-MG), is a joint effort 
of the International MG/COVID-19 
Working Group and neurologists who 
help to take care of patients with 
myasthenia gravis globally and was 
formally launched on April 9, 2020. 
Registry data elements, inclusion and 
exclusion criteria, and research study 
approval are available in the appendix 
(appendix pp 7–8). The registry is still 
open and active accrual continues 
through electronic-form or paper-
form submission of case reports. Data 
entry for each case submission takes 
approximately 10 min. Additional 
study details and steps for case 
submission are available from the 
Myasthenia Gravis Foundation of 
America website.6
A total of 91 patients with myas thenia 
gravis were included at the time of 
interim analysis (Oct 5, 2020; appendix 
pp 10–12). Myasthenia gravis worsen-
ing or crisis requiring rescue therapy 
(eg, intravenous immunoglobulin, 
plasma exchange, or steroids) in the 
setting of COVID-19 was reported 
in 36 (40%) of 91 patients. Com-
plete recovery or discharge to home 
was reported in 39 (43%) patients, 
whereas 22 (24%) patients died due to 
COVID-19.
These preliminary data suggest that 
a global, physician-reported registry 
is feasible during times of crisis, even 
for rare diseases, such as myasthenia 
gravis. Current data, which might 
be biased toward poor outcomes 
reporting, show that patients with 
myasthenia gravis who are infected 
with severe acute respiratory syndrome 
coronavirus 2 are frequently admitted 
to hospital, have disease exacerbations, 
and have a higher mortality than the 
general population with COVID-19.5 
More neurologists and neuromuscular 
specialists from across the globe 
need to submit details of cases to the 
CARE-MG registry if it is to become 
more representative—in terms of 
contributing physicians, patients, and 
results—and provide the information 
necessary to enable evidence-based 
care for patients with myasthenia 
gravis during this pandemic.
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also show that many students apply 
to other departments and switch to 
neurosurgery only after not being 
accepted for their first choice. We 
believe that the long training period, 
low wages, and heterogeneity of clinical 
performance across different hospitals 
might discourage the best candidates 
from a career in this field.
In 2014, the National Health 
Commission established standardised 
training for residents, which extended 
the training period to 3 years. Stan-
darised 2–4-year training periods for 
some specialists (eg, 2 years for general 
surgery and 4 years for neurosurgery) 
were implemented in 2017.4,5 All newly 
licensed doctors who want to specialise 
in neurosurgery, respiratory and critical 
care medicine, or cardiology must 
now complete extended specialist 
training after finishing their residential 
training. Although wages for residents 
have improved, they are still below the 
average income in other professional 
fields (eg, ophthalmology).
The heterogeneity in medical 
standards of neurosurgical depart-
ments across China might also pose 
a problem. In most hospitals, neuro-
surgeons only manage patients with 
traumatic brain injury or intracranial 
haemorrhage, and they do not operate 
on brain tumours or do endovascular 
therapy for intracranial aneurysms. 
The rewards and challenges of com-
plex neurosurgical interventions are 
restricted to a few hospitals, most of 
which are located in eastern China.
We encourage every young trainee 
to try their best for a rewarding neu-
ro surgi cal career in China. How ever, 
solutions to the rec ruitment and reten-
tion of new neurosurgeons are needed.
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Training neurosurgeons 
in China 
In their Correspondence, Norton and 
colleagues1 remarked that neurosurgery 
should be an attractive option for the 
best medical students, regardless of 
gender, ethnicity, or socioeconomic 
status. However, this might not be 
the case in China. Because of the skills 
and knowledge that neurosurgical 
depart ments demand, recruitment 
of students is not easy. For example, 
in some institutions, neurosurgery 
students had a lower admission score 
than those in other clinical specialties, 
such as orthopaedics and cardiol-
ogy.2,3 Data from the Beijing Institute 
of Neurosurgery, Beijing, China, and 
Department of Neurosurgery, The First 
Clinical Medicine College, Southern 
Medical University, Guangzhou, China, 
